Biomedtracker performed a 5-question survey of 39 United States and European (France, Germany, Italy, and United Kingdom) oncologists after the American Society of Clinical Oncology (ASCO) meeting to gauge interest in new data presented on drugs in clinical development.
Candidate drugs and indications covered include: abemaciclib (Eli Lilly) and Ibrance (Pfizer) for breast cancer, RG788 and Tecentriq (Roche) for solid tumors, and avelumab (Merck) for mesothelioma.